Regeneron Pharmaceut

REGN
Real-time BATS EXCHANGE - 11/12 01:47:41 pm
346.675USD
+0.69%
Prev.344.2800
Open344.0000
High349.9400
Low341.3600
Volume405 384
Financials
Sales 2019 7 780 M
EBIT 2019 2 258 M
Net income 2019 1 957 M
Finance 2019 5 371 M
Yield 2019 -
P/E ratio 2019 18,9x
P/E ratio 2020 15,0x
EV / Sales2019 3,87x
EV / Sales2020 3,41x
Capitalization 35 474 M
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows:
- sales of products (61.2%);
- supply of collaborative services (32.6%): working with Sanofi...
Sector :
Bio Therapeutic Drugs
Calendar :
2019-11-12 Presentation
Trading Rating :
Investor Rating :
Latest news
07:31aREGENERON PHARMACEUTICALS : Announces Upcoming Investor Conference Presentations
PR
11/06REGENERON PHARMACEUTICALS : to Report Results from CD20xCD3 and BCMAxCD3 Bispecifics and C5 Antibody Programs at ASH Annual meeting
PU
11/06REGENERON PHARMACEUTICALS : Provides Updates on Phase 3 Libtayo Development Program in Advanced Non-small Cell Lung Cancer
AQ
11/06Biogen Adding Ophthalmology Biosimilars in Deal With Samsung Bioepis
DJ
11/06REGENERON PHARMACEUTICALS : and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer
PR
11/05Regeneron Pharmaceuticals Up Over 9%, on Pace for Largest Percent Increase Since November 2016 -- Data Talk
DJ
11/05REGENERON PHARMACEUTICALS : Board Approves $1 Billion Buyback
DJ
11/05REGENERON PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBullishNeutral
Resistance360360440
Spread/Res.-3,3%-3,3%-21%
Spread/Supp.14%14%27%
Support305305273